Research programme: MEK inhibitors - Atriva Therapeutics

Drug Profile

Research programme: MEK inhibitors - Atriva Therapeutics

Latest Information Update: 10 Nov 2016

Price : $50

At a glance

  • Originator University of Muenster
  • Developer Atriva Therapeutics
  • Class Antibacterials; Antivirals
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Bacterial infections; Influenza virus infections

Most Recent Events

  • 04 Nov 2016 Atriva Therapeutics receives patent allowance for MEK inhibitors in USA
  • 05 Jul 2016 Atriva Therapeutics has patents pending for MEK inhibitors for treatment of bacterial co-infections in Germany
  • 05 Jul 2016 Early research in Bacterial infections in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top